SCHEMBL609252

SCHEMBL609252

COc1ccc(CCNc2ccc(O)c(C(=O)O)c2)cc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SYK P43405 1/20 0.60
MAPT P10636 4/20 0.55
KDM4C Q9H3R0 2/20 0.52
PPARA Q07869 1/20 0.52
STING1 Q86WV6 1/20 0.52
PTGDR Q13258 1/20 0.49
FPR2 P25090 3/20 0.49
FFAR1 O14842 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
ALDH1A1 P00352 2/20 0.48
THRA P10827 1/20 0.47
THRB P10828 1/20 0.47
NOX4 Q9NPH5 2/20 0.47
RGS12 O14924 1/20 0.47
EGFR P00533 1/20 0.47
LCK P06239 1/20 0.47
CAMKK2 Q96RR4 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29391099 0.87 KDM4C (0.69) SYKMAPTKDM4CPPARASTING1
SCHEMBL610076 0.87 KDM4C (0.69) SYKMAPTKDM4CPPARASTING1
SCHEMBL4095004 0.85 KDM4C (0.56) SYKMAPTKDM4CPPARASTING1
SCHEMBL4089153 0.85 PPARA (0.50) SYKMAPTKDM4CPPARASTING1
SCHEMBL3419319 0.85 KDM4C (0.50) SYKMAPTKDM4CPPARASTING1
SCHEMBL608754 0.84 NOX4 (0.61) SYKMAPTKDM4CPPARASTING1
SCHEMBL610123 0.83 SYK (0.58) SYKMAPTKDM4CPPARASTING1
SCHEMBL29388077 0.83 SYK (0.58) SYKMAPTKDM4CPPARASTING1
SCHEMBL1250220 0.82 KDM4C (0.58) SYKMAPTKDM4CPPARASTING1
SCHEMBL608498 0.81 KDM4C (0.53) SYKMAPTKDM4CPPARASTING1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3902536-B1 COMPOSITIONS COMPRISING 5-BENZYLAMINOSALICYLIC ACID COMPOUNDS FOR USE IN TREATING NEURODEGENERATIVE DISORDERS IN A COMPANION ANIMAL GNT PHARMA CO LTD (KR) 2025-09-03 EP claimed
EP-4456890-A2 COMPOSITIONS AND METHODS FOR TREATING PULMONARY DISORDERS GNT Pharma Co., Ltd (KR) 2024-11-06 EP claimed
WO-2023156808-A2 COMPOSITIONS AND METHODS FOR TREATING PULMONARY DISORDERS GNT PHARMA CO., LTD. (KR) 2023-08-24 WO claimed
US-20230233503-A1 COMPOSITIONS AND METHODS FOR TREATING PULMONARY DISORDERS GNT PHARMA CO., LTD. (KR) 2023-07-27 US claimed
US-20220249343-A1 COSMETIC COMPOSITION INCLUDING 5-BENZYLAMINOSALICYLIC ACID DERIVATIVE, AND TOPICAL USE THEREOF GNT PHARMA CO., LTD. (KR) 2022-08-11 US claimed
US-20220241231-A1 COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISORDERS GNT PHARMA CO., LTD. (KR) 2022-08-04 US claimed
EP-3998058-A1 COSMETIC COMPOSITION COMPRISING 5-BENZYLAMINOSALICYLIC ACID DERIVATIVE AND LOCAL ADMINISTRATION METHOD THEREOF GNT Pharma Co., Ltd (KR) 2022-05-18 EP claimed
CN-114096227-A Cosmetic compositions comprising 5-benzylaminosalicylic acid derivatives and methods of topical use thereof 吉恩特药业株式会社 2022-02-25 CN claimed
CN-113710242-A Compositions and methods for treating neurodegenerative disorders 吉恩特药业株式会社 2021-11-26 CN claimed
EP-3902536-A1 COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISORDERS GNT Pharma Co., Ltd (KR) 2021-11-03 EP claimed
WO-2021006637-A1 COSMETIC COMPOSITION COMPRISING 5-BENZYLAMINOSALICYLIC ACID DERIVATIVE AND LOCAL ADMINISTRATION METHOD THEREOF 주식회사 지엔티파마 2021-01-14 WO claimed
US-20200206172-A1 COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISORDERS GNT PHARMA CO., LTD. (KR) 2020-07-02 US claimed
WO-2020136441-A1 COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISORDERS GNT PHARMA CO., LTD. (KR) 2020-07-02 WO claimed
EP-2004164-B1 PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING INFLAMMATORY DISEASES NEUROTECH PHARMACEUTICALS CO LTD (KR) 2018-08-08 EP claimed
US-20130316988-A1 Pharmaceutical Composition for Treating or Preventing Degenerative and Inflammatory Diseases NEUROTECH PHARMACEUTICALS CO., LTD. (KR) 2013-11-28 US claimed
US-8455470-B2 Pharmaceutical composition for treating or preventing degenerative and inflammatory diseases NEUROTECH PHARMACEUTICALS CO., LTD (KR) 2013-06-04 US claimed
US-20120040939-A1 MEDICINAL USE OF 5-BENZYLAMINOSALICYLIC ACID DERIVATIVE OR ITS SALT NEUROTECH PHARMACEUTICALS CO., LTD. (KR) 2012-02-16 US claimed
US-20090281181-A1 Pharmaceutical Composition for Treating or Preventing Degenerative and Inflammatory Diseases GNT PHARMA CO., LTD. (KR) 2009-11-12 US claimed
EP-2004164-A1 PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING DEGENERATIVE AND INFLAMMATORY DISEASES Neurotech Co., Ltd. (KR) 2008-12-24 EP claimed
WO-2007119973-A1 PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING DEGENERATIVE AND INFLAMMATORY DISEASES NEUROTECH CO., LTD. (KR) 2007-10-25 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230233503-A1 COMPOSITIONS AND METHODS FOR TREATING PULMONARY DISORDERS HAO2, ACOX1, HAO1 SYK 2333/4885MAPT 3976/4885KDM4C 3145/4885
US-20220241231-A1 COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISORDERS PRNP, PSEN1, GRIK5 SYK 3071/4885MAPT 19/4885KDM4C 2280/4885
US-20120040939-A1 MEDICINAL USE OF 5-BENZYLAMINOSALICYLIC ACID DERIVATIVE OR ITS SALT HTR5A, HTR6, MC5R SYK 1284/4885MAPT 2420/4885KDM4C 2416/4885
US-20090281181-A1 Pharmaceutical Composition for Treating or Preventing Degenerative and Inflammatory Diseases ALOX12, ALOX15, ALOX15B SYK 1765/4885MAPT 654/4885KDM4C 4051/4885
US-20130316988-A1 Pharmaceutical Composition for Treating or Preventing Degenerative and Inflammatory Diseases ALOX12, ALOX15, ALOX15B SYK 1765/4885MAPT 654/4885KDM4C 4051/4885
US-20220249343-A1 COSMETIC COMPOSITION INCLUDING 5-BENZYLAMINOSALICYLIC ACID DERIVATIVE, AND TOPICAL USE THEREOF ALOX5, ALOX15, IL5 SYK 2252/4885MAPT 3381/4885KDM4C 1095/4885
US-20200206172-A1 COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISORDERS PRNP, PSEN1, GRIK5 SYK 3071/4885MAPT 19/4885KDM4C 2280/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.